Article

Robert Gamble Talks about the Challenges Payers and Providers Face in Oncology Management

In this video, Robert Bo Gamble, Director, Strategic Practice Initiatives, Community Oncology Alliance, Washington, DC, says that it is critical for payers and providers to come together in oncology management.

In this video, Robert “Bo” Gamble, Director, Strategic Practice Initiatives, Community Oncology Alliance, Washington, DC, says that it is critical for payers and providers to come together in oncology management. Consensus, communication, and collaboration between payers and providers is key to effectively working together in cancer care.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Martin Engelke
David Awad, PharmD, BCOP
Dr Adela Perolla
Dr Adela Perolla | Image Credit: - stock.adobe.com
Dr Ola Landgren
Dr Ola Landgren
Andrew Kuykendall, MD, Moffitt Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Dirk Arnold, MD, PhD, medical director, Asklepios Tumour Biology Centre
Related Content
Participants who received RGX-202 demonstrated functional improvement and better outcomes than controls for all measures. | Image Credit: Treecha- stock.adobe.com
June 12th 2025

RGX-202 Gene Therapy Improves DMD Trajectory, Biomarkers

Rose McNulty
Participants with Duchenne muscular dystrophy (DMD) who received RGX-202 demonstrated functional improvement and better outcomes than natural history controls for all measures.
managed care cast logo
June 10th 2025

Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs

Brooke McCormick Julia D. Lucaci, PharmD, MS
Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.
The timing of initiation to immunotherapy, either with the first cycle of chemotherapy or within 21 days of diagnosis, does not significantly affect outcomes in ES-SCLC. | Image Credit: Bonsales - stock.adobe.com
June 12th 2025

Immunotherapy Timing Does Not Significantly Affect Outcomes in ES-SCLC

Jared Kaltwasser
The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small cell lung cancer (ES-SCLC), a study found.
managed care cast logo
May 29th 2025

Laundromats as a New Frontier in Community Health, Medicaid Outreach

Brooke McCormick Lindsey Jeanne Leininger, PhD Allister Chang, MPA
Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
AJMC
June 11th 2025

Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

Brigham Walker, PhD Lalan Wilfong, MD Nicholas Robert, MD Alexander Siebert, PhD J. Russell Hoverman, MD, PhD
A private oncology shared savings plan reduced colon cancer treatment costs. Results varied by tumor, with none in breast cancer and mixed effects in lung cancer.
Tirzepatide injections in box | Image credit: MKPhoto – stock.adobe.com
June 10th 2025

Real-World Use of GLP-1s Yields Less Weight Loss Than Clinical Trials

Hayden E. Klein
Patients who remained on treatment, especially at higher doses or on tirzepatide, were more likely to achieve clinically meaningful weight loss and improved glycemic control.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo